The Shared Longevity Pathway: mTORC1, AMPK, and IGF-1
All three dietary longevity strategies converge on the same nutrient-sensing network that governs the cellular balance between growth and maintenance:
- mTORC1 (mechanistic target of rapamycin complex 1): The master growth regulator, activated by amino acids (via Ragulator-Rag GTPases), growth factors (insulin, IGF-1 via PI3K/AKT), and sufficient energy status (via AMPK inhibition). When mTORC1 is active, cells prioritize growth, protein synthesis, and cell division. When mTORC1 is inactive (nutrient scarcity), cells shift to maintenance, autophagy, stress resistance, and repair. CR, TRE, and FMD all suppress mTORC1 via different inputs: CR lowers circulating amino acids and insulin chronically; TRE creates daily mTORC1-off windows; FMD creates 5-day mTORC1-off periods monthly.
- AMPK (AMP-activated protein kinase): The energy sensor activated when AMP:ATP ratio rises (energy depletion). AMPK phosphorylates and inhibits mTORC1 (via TSC1/2 and Raptor), activates autophagy (via ULK1), increases mitochondrial biogenesis (via PGC-1α), and promotes fatty acid oxidation. All fasting protocols activate AMPK; the duration and depth of activation differs.
- IGF-1 axis: The primary mediator of growth hormone's systemic effects. IGF-1 activates the PI3K/AKT/mTORC1 axis in virtually every cell type. Dietary protein is the primary driver of hepatic IGF-1 secretion — low protein intake is the most efficient dietary IGF-1 suppressor. This explains why caloric restriction that maintains high protein intake produces less IGF-1 reduction than equivalent restriction with proportional protein reduction.
Caloric Restriction: The CALERIE Evidence
CALERIE Phase 2 (Ravussin 2015) enrolled 218 healthy, non-obese adults (BMI 22–28) randomized 2:1 to 25% caloric restriction vs ad libitum eating for 24 months. It is the largest and longest rigorous CR trial in non-obese humans. Key findings:
- Achieved restriction: 11.9% (participants couldn't maintain 25% over 2 years — real-world compliance limits CR depth)
- Body weight: −7.5kg vs +0.1kg control
- IGF-1: −10.4% reduction (Kraus 2019) — the key longevity biomarker
- Cardiometabolic: −33% improvement in Framingham 10-year CVD risk score
- Oxidative stress (F2-isoprostanes): significantly reduced
- Thyroid axis: T3 reduction, T4 stable — the CR thyroid phenotype seen in long-lived animal models
- Quality of life, mood, sexual function: non-significantly different from control — addressing concerns that CR would reduce wellbeing
- Bone density: mild reduction with weight loss — the primary safety concern for long-term CR
The CALERIE data established that even modest, achievable caloric restriction in healthy non-obese adults produces meaningful improvements in the molecular biomarkers of aging. The limitation: it cannot tell us whether these biomarker improvements translate to extended human lifespan — that trial would require 40+ years and tens of thousands of participants.
Fasting Mimicking Diet: The Longo Protocol
Valter Longo's FMD (ProLon commercial product) is a 5-day monthly protocol providing 750–1,100 kcal/day (Day 1: 1,100 kcal; Days 2–5: 750 kcal) in a specific macronutrient composition: ~10% protein, ~56% fat, ~34% carbohydrate. The low protein content is the primary IGF-1 suppressor; the high fat content maintains a mild ketogenic state; the moderate carbohydrates prevent severe glucose suppression. The key claim: this specific composition maintains "fasting-like" physiological effects (IGF-1 suppression, autophagy, stem cell activation) while providing enough calories to be sustainable and reduce compliance burden vs complete fasting.
The mouse data is impressive: periodic FMD extended median lifespan by 11% in C57BL/6 mice, reduced visceral fat, improved cognitive function in old age, and promoted tissue regeneration. The human Phase 1 data (Brandhorst 2015, n=19): 3 monthly FMD cycles produced −5.7kg weight, −11.7% IGF-1, −21% triglycerides, reduced CRP. The most recent Phase 2 data (Longo 2021, Cell Metab, n=100): confirmed the metabolic benefits and showed regeneration markers (stem cell mobilization biomarkers) in a larger cohort.
| Protocol | Mechanism Timing | IGF-1 Effect | Compliance Profile | Best Evidence |
|---|---|---|---|---|
| Caloric restriction (−20–25% daily) | Chronic, sustained mTORC1 suppression; continuous IGF-1 reduction | −10–15% (achieved restriction dependent) | Difficult long-term; 11.9% actual vs 25% target in CALERIE over 2 years | CALERIE: best human biomarker data; NIA rodent ITP: most consistent longevity data across labs |
| Time-restricted eating (16:8 or 18:6) | Daily mTORC1-off windows (16–18h); circadian alignment component distinct | Modest reduction in some studies; primarily insulin/glucose improvement | Highest compliance (skip breakfast, eat noon–8pm); sustainable indefinitely for most people | Sutton 2018 (eTRE, insulin sensitivity); Wilkinson 2020 (TREAT trial, metabolic syndrome); limited long-term data |
| Fasting mimicking diet (5 days/month) | Pulsed 5-day mTORC1 suppression; deep autophagy induction; stem cell mobilization during refeeding | −11–15% per cycle; returns toward baseline between cycles | Moderate — 5 difficult days/month; between cycles, no dietary restriction | Brandhorst 2015 (Phase 1 human); Longo 2021 (Phase 2); ongoing breast cancer trials |
| Prolonged fasting (3–5 days water fast) | Deepest acute mTORC1 suppression; ketosis; maximum autophagy flux; highest stem cell activation signal | Maximum reduction (similar to FMD but more acute) | Very low — medically supervised; safety concerns without monitoring; not sustainable as routine | Cahill classic studies (physiological); limited RCT data; case series in cancer patients |
Choosing the Right Protocol: Evidence-Based Decision Framework
- Best compliance-to-evidence ratio: TRE + monthly FMD combination: TRE (16:8 daily) has the highest sustainable compliance and requires no caloric counting or food restriction — just time. Layering one 5-day FMD cycle monthly provides the pulsed deep IGF-1 suppression and autophagy induction that daily TRE doesn't produce. The two protocols are mechanistically complementary: TRE maintains daily AMPK activation and circadian alignment; FMD provides monthly mTORC1 suppression deep enough to trigger stem cell mobilization and tissue regeneration signals. Together they cover both the chronic and pulsed longevity pathway activation.
- Protein restriction is the most potent IGF-1 lever in CR: The CALERIE participants who maintained protein at high levels (>1.2g/kg) showed less IGF-1 reduction than those who proportionally reduced protein. Fontana's research demonstrates that CR with maintained high protein is much less effective at reducing IGF-1 than equivalent CR with proportional protein reduction. If IGF-1 lowering is a goal, restricting protein to 0.7–0.8g/kg (adequate but not excessive) combined with caloric restriction is the most effective dietary approach — consistent with Longo's "low but adequate protein" FMD design.
- TRE timing matters: earlier eating windows produce larger benefits: Sutton 2018's key finding was that an early TRE window (7am–3pm) improved insulin sensitivity, blood pressure, and oxidative stress WITHOUT caloric restriction or weight loss — while a late window (12pm–8pm) produced fewer benefits. The mechanism: circadian insulin sensitivity peaks in the morning (morning cortisol → higher glucose disposal), and eating in alignment with this peak reduces postprandial glucose excursions. Practical implementation: move breakfast earlier, advance dinner to 5–6pm, stop eating by 7pm. This is more impactful than simply skipping breakfast and eating until 8pm.
- FMD DIY vs ProLon commercial: The ProLon commercial kit (~$250/box) provides the exact macronutrient composition studied in clinical trials (specific L-Nutrient soups, nut bars, teas, and supplements). DIY FMD following Longo's published macronutrient guidelines (750–1,100 kcal, 10% protein, 56% fat, 34% carbohydrate from whole foods) is substantially cheaper but may not replicate the precise micronutrient composition. For health optimization (vs the clinical cancer trials), DIY with careful composition tracking is a reasonable alternative. The ProLon kit provides the documented protocol without calculation burden.
- Who should NOT practice aggressive dietary restriction: Pregnant and breastfeeding women; individuals with or in recovery from eating disorders; underweight individuals (BMI <18.5); type 1 diabetics (hypoglycemia risk without medical supervision); individuals on medications requiring food timing (metformin, certain antibiotics, thyroid medications); those with a history of gallstones (rapid weight loss and fasting accelerate gallstone formation). For these populations, the mild-restriction end of the spectrum (reducing ultra-processed food consumption, maintaining protein adequacy, avoiding late-night eating) provides meaningful longevity pathway benefits with minimal risk.
ProLon is the commercially available version of Longo's clinically studied FMD protocol — the macronutrient composition (L-Nutrient soups, nut bars, teas, olives, supplements) matches what was used in the Brandhorst 2015 and Longo 2021 publications. Recommended: one 5-day cycle per month for 3 months, then assess biomarkers. Not recommended for underweight individuals, those with eating disorder history, T1DM, or pregnancy. Consult your physician before starting if you have chronic conditions or take daily medications.